ClinicalTrials.gg
Enrolling by invitationNCT06126380Updated Dec 10, 2025

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

A Phase 2 interventional study of AT-1501 and Tacrolimus in Kidney Transplant Rejection, sponsored by Eledon Pharmaceuticals. Enrolling by invitation at 43 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by Eledon Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Planned enrollment
179th of 638
132 · median 48
Started
2023
with 29 others
Phase 2
87 of 765
4 open now
Primary completion
2029-12
later than 87 of 96 live
Registered
707th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 179th largest by planned enrollment of the 638 interventional ones that give a count, is one of 30 that started in 2023, is one of 87 in phase 2, reaches primary completion later than 87 of the 96 other live ones, and was the 707th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the long term safety and efficacy of AT-1501 (tegoprubart) compared with tacrolimus in patients undergoing kidney transplantation.

Read the detailed description

This is a multicenter, open-label, active control extension study to assess the long-term safety and efficacy of AT-1501 (tegoprubart) compared with tacrolimus in the preservation of allograft function after kidney transplantation.

The number of patients enrolled for OLE study will depend on the enrollment in the Parent studies. To be eligible for participation in this study, participants must have completed a designated Parent study.

Participants in this study will continue the treatment regimen they were receiving in the Parent study. Dose regimens will include either AT-1501 (tegoprubart) or tacrolimus.

03

Conditions studied

  • Kidney Transplant Rejection

Keywords

  • Kidney Transplant
  • AT-1501
  • Renal Allograft Rejection
  • Prophylaxis
  • CD40L Inhibitor
  • Humanized blocking antibody to CD40L
  • monoclonal antibody
  • renal, transplant
  • ESRD
  • tegoprubart
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successfully completed qualifying Parent study, where entry into the OLE was offered;
  • Continue to be able to understand the key components of the study as described in the written ICF, and is willing and able to provide written ;
  • Agree not to participate in another interventional study while on treatment;
  • If female, is surgically sterile or 2 years . Women of may be enrolled if a pregnancy test is negative at baseline. Women of childbearing potential and men with partners that are of childbearing potential must agree to use highly effective methods of from baseline, through 90 days after the last administration of the study drug. Examples of acceptable methods of contraception are described in Table 6.
  • If male, agree to use a medically accepted highly effective method of contraception and agree to use this method for 90 days after last administration of the study drug and agree to not donate sperm for 90 days after last administration of the study drug.

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unlikely to comply with the study requirements, in the opinion of the Investigator;
  • Met any of the stopping criteria or discontinued study drug in the Parent study;
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    AT-1501

    AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg per os (orally) (PO) twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent

    Drug: AT-1501

  • Active comparator
    Tacrolimus

    Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent

    Drug: Tacrolimus

Interventions

  • AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent

    Also known as: Tegoprubart

  • Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability - Incidence of Treatment Emergent Adverse Events

    Incidence of treatment-emergent serious adverse events (TESAEs), treatment-emergent adverse events (TEAEs), and treatment-emergent AEs of special interest (TEAEoSI).

    Time frame: Assessed from date of enrollment through Month 48

  2. Safety and Tolerability - Kidney Transplant Medication Side Effects

    Kidney transplant medication side effects using the Modified Transplant Symptom Occurrence and Symptom Distress Scale-59 (MTSOSD) at baseline and 12, 24, 36, and 48 months.

    Time frame: Assessed from date of enrollment through Month 48

Secondary outcomes

  1. The proportion of patient and graft survival at 12, 24, 36, and 48 months

    A participant is considered to have graft functional impairment if they have an eGFR \<60 mL/min/1.73m\^2.

    Time frame: Assessed from date of enrollment through Month 48

  2. The proportion of participants with Graft function impairment at 12, 24, 36, and 48 months

    A participant is considered to have graft functional impairment if they have an eGFR \<60 mL/min/1.73m\^2.

    Time frame: Assessed from date of enrollment through Month 48

  3. Proportion of participants with BPAR at 12, 24, 36, and 48 months

    The Proportion of participants with BPAR at 12, 24, 36, and 48 months.

    Time frame: Assessed from date of enrollment through Month 48

  4. Proportion of composite endpoint (graft failure, BPAR, or death) at 12, 24, 36, and 48 months

    The Proportion of participants with composite endpoint (graft failure, BPAR, or death) at 12, 24, 36, and 48 months.

    Time frame: Assessed from date of enrollment through Month 48

07

Study locations

43 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2029, 74 months after the start.

Of 26 industry-sponsored phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 74 months is above that.

Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Nov 13, 2023
StartActual
Oct 25, 2023
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06126380
Lead sponsor
Eledon Pharmaceuticals
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Oct 25, 2023
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Dec 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprubart

Start the discussion